JW Pharmaceutical said on the 3rd that its sales, operating profit, and net profit all posted the highest third-quarter results on record this year.
On a separate basis, third-quarter operating profit was 32.6 billion won, up 23.9% from the same period a year earlier. Revenue was 198.6 billion won, up 12.5% from the same period a year earlier, and net profit was 30.8 billion won, up 56.3%.
The prescription drug (ETC) institutional sector posted third-quarter sales of 166.5 billion won, up 11.4% from 149.4 billion won a year earlier, driving performance growth. In the same period, the dyslipidemia treatment "Livalozet" rose 39.2% to 26.5 billion won. Total sales of the Livalo family (Livalo, Livalozet, Livalo-V) increased 22.2% to 48.4 billion won. Sales of the hemophilia treatment "Hemlibra" rose 61.1% to 20 billion won, and sales of the high-dose iron injection "Ferinject" recorded growth in the 40% range at 4.8 billion won.
The infusion solutions institutional sector recorded sales of 67.8 billion won, up 7.6%. The total parenteral nutrition product line "Winuf" rose 8.4% to 23.3 billion won, and basic solutions increased 3.6% to 22.2 billion won. The enteral nutrition solution "Encover" increased 17.1% to 9.6 billion won.
The over-the-counter drugs institutional sector posted third-quarter sales of 13.3 billion won, up 26.9%. The company said first-half OTC sales fell from a year earlier, but returned to growth in the third quarter.
A JW Pharmaceutical official said, "Sales growth of original drugs with product competitiveness and of the institutional sector for infusion solutions is supporting the performance trend," adding, "Based on this, we will continue our R&D investment stance to further solidify a virtuous-cycle structure."